Endovascular thrombectomy time metrics in the era of COVID-19: observations from the Society of Vascular and Interventional Neurology Multicenter Collaboration.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 21 12 2020
revised: 23 01 2021
accepted: 25 01 2021
pubmed: 10 2 2021
medline: 21 1 2022
entrez: 9 2 2021
Statut: ppublish

Résumé

Unprecedented workflow shifts during the coronavirus disease 2019 (COVID-19) pandemic have contributed to delays in acute care delivery, but whether it adversely affected endovascular thrombectomy metrics in acute large vessel occlusion (LVO) is unknown. We performed a retrospective review of observational data from 14 comprehensive stroke centers in nine US states with acute LVO. EVT metrics were compared between March to July 2019 against March to July 2020 (primary analysis), and between state-specific pre-peak and peak COVID-19 months (secondary analysis), with multivariable adjustment. Of the 1364 patients included in the primary analysis (51% female, median NIHSS 14 [IQR 7-21], and 74% of whom underwent EVT), there was no difference in the primary outcome of door-to-puncture (DTP) time between the 2019 control period and the COVID-19 period (median 71 vs 67 min, P=0.10). After adjustment for variables associated with faster DTP, and clustering by site, there remained a trend toward shorter DTP during the pandemic (β In this multi-center study, there was no delay in EVT among patients treated for intracranial occlusion during the COVID-19 era compared with the pre-COVID era.

Sections du résumé

BACKGROUND BACKGROUND
Unprecedented workflow shifts during the coronavirus disease 2019 (COVID-19) pandemic have contributed to delays in acute care delivery, but whether it adversely affected endovascular thrombectomy metrics in acute large vessel occlusion (LVO) is unknown.
METHODS METHODS
We performed a retrospective review of observational data from 14 comprehensive stroke centers in nine US states with acute LVO. EVT metrics were compared between March to July 2019 against March to July 2020 (primary analysis), and between state-specific pre-peak and peak COVID-19 months (secondary analysis), with multivariable adjustment.
RESULTS RESULTS
Of the 1364 patients included in the primary analysis (51% female, median NIHSS 14 [IQR 7-21], and 74% of whom underwent EVT), there was no difference in the primary outcome of door-to-puncture (DTP) time between the 2019 control period and the COVID-19 period (median 71 vs 67 min, P=0.10). After adjustment for variables associated with faster DTP, and clustering by site, there remained a trend toward shorter DTP during the pandemic (β
CONCLUSIONS CONCLUSIONS
In this multi-center study, there was no delay in EVT among patients treated for intracranial occlusion during the COVID-19 era compared with the pre-COVID era.

Identifiants

pubmed: 33558439
pii: neurintsurg-2020-017205
doi: 10.1136/neurintsurg-2020-017205
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Alexandra L Czap (AL)

Neurology, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, USA.

Alicia M Zha (AM)

Neurology, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, USA.

Jacob Sebaugh (J)

Neurology, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, USA.

Ameer E Hassan (AE)

Department of Neurology, University of Texas Rio Grande Valley, Harlingen, Texas, USA.
Clinical Neuroscience Research, Valley Baptist Medical Center, Harlingen, Texas, USA.

Julie G Shulman (JG)

Neurology, Boston Medical Center, Boston, Massachusetts, USA.

Mohamad Abdalkader (M)

Neurology, Boston Medical Center, Boston, Massachusetts, USA.

Thanh N Nguyen (TN)

Neurology, Boston Medical Center, Boston, Massachusetts, USA.
Radiology, Boston Medical Center, Boston, Massachusetts, USA.
Interventional Neuroradiology and Endovascular Neurosurgery, Boston Medical Center, Boston, Massachusetts, USA.

Italo Linfante (I)

Department of Interventional Neuroradiology and Endovascular Neurosurgery, Baptist Health South Florida, Coral Gables, Florida, USA.

Amy Kathryn Starosciak (AK)

Center for Outcomes Research, Baptist Health South Florida, Coral Gables, Florida, USA.

Santiago Ortega-Gutierrez (S)

Neurology, Neurosurgery and Radiology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

Mudassir Farooqui (M)

Neurology, Neurosurgery and Radiology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

Darko Quispe-Orozco (D)

Neurology, Neurosurgery and Radiology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

Nirav A Vora (NA)

Neuroscience Center, Riverside Methodist Hospital, Columbus, Ohio, USA.

Vivek Rai (V)

Neuroscience Center, Riverside Methodist Hospital, Columbus, Ohio, USA.

Raul G Nogueira (RG)

Neurology, Grady Memorial Hospital, Atlanta, Georgia, USA.

Diogo C Haussen (DC)

Neurology, Grady Memorial Hospital, Atlanta, Georgia, USA.

Dinesh V Jillella (DV)

Neurology, Emory University, Atlanta, Georgia, USA.

Ameena Rana (A)

Cooper Medical School of Rowan University, Camden, New Jersey, USA.

Siyuan Yu (S)

Cooper Medical School of Rowan University, Camden, New Jersey, USA.

Jesse M Thon (JM)

Cooper Neurological Institute, Cooper University Health Care, Camden, New Jersey, USA.

Osama O Zaidat (OO)

Neuroscience Institute, Bons Secours Mercy Health St. Vincent Hospital, Toledo, Ohio, USA.

Priyank Khandelwal (P)

Neurology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

Ivo Bach (I)

Neurology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

Sunil A Sheth (SA)

Neurology, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, USA.

Ashutosh P Jadhav (AP)

Neurology, University of Pittsburgh Medical Center Mercy Hospital, Pittsburgh, Pennsylvania, USA.
Neurology, University of Pittsburgh Medical Center Presbyterian Medical Center, Pittsburgh, Pennsylvania, USA.

Shashvat M Desai (SM)

Neurology, University of Pittsburgh Medical Center Mercy Hospital, Pittsburgh, Pennsylvania, USA.
Neurology, University of Pittsburgh Medical Center Presbyterian Medical Center, Pittsburgh, Pennsylvania, USA.

Tudor G Jovin (TG)

Cooper Neurological Institute, Cooper University Health Care, Camden, New Jersey, USA.

David S Liebeskind (DS)

Neurology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA.

James E Siegler (JE)

Cooper Neurological Institute, Cooper University Health Care, Camden, New Jersey, USA siegler.james@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH